N-(tert-butyl)-4-ethoxybenzamide | 333348-76-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(tert-butyl)-4-ethoxybenzamide
• 英文别名: N-tert-butyl-4-ethoxybenzamide
• CAS: 333348-76-8
• 化学式: C₁₃H₁₉NO₂
• mdl: MFCD01216116
• 分子量: 221.299
• InChiKey: QMWNCXWMWTUVJK-UHFFFAOYSA-N

物化性质

• 沸点：
  359.8±25.0 °C(Predicted)
• 密度：
  1.006±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  对乙氧基苯腈 、 叔丁醇 在 aluminum hydrogen sulfate 作用下， 以 硝基甲烷 为溶剂， 反应 3.0h， 以93%的产率得到N-(tert-butyl)-4-ethoxybenzamide
  参考文献：
  名称：

  Al（HSO 4）3的Ritter反应在异质条件下高效便捷地合成N-取代的酰胺

  摘要：

  通过脂肪族和芳香族腈与各种苄醇（仲和叔）和叔丁醇的反应，通过硫酸铝[Al（HSO 4）催化的Ritter反应使硝基甲烷回流，从而有效而廉价地合成N-取代的酰胺描述图3。该催化剂是空气稳定的，具有成本效益的固体酸，可以通过过滤容易地再循环并重复使用四次，而不会显着降低其活性。 描述了通过经由硫酸氢铝[Al（HSO 4）3 ]催化的Ritter反应使硝基甲烷回流而有效且廉价地合成N-取代的酰胺的方法。该催化剂是空气稳定的，具有成本效益的固体酸，可以通过过滤容易地再循环并重复使用四次，而活性没有任何显着损失。

  DOI：

  10.1007/s12039-016-1036-x

文献信息

• Palladium/Copper-Catalyzed Oxidative Coupling of Arylboronic Acids with Isocyanides: Selective Routes to Amides and Diaryl Ketones
  作者：Fangling Lu、Ziyue Chen、Zhen Li、Xiaoyan Wang、Xinyue Peng、Cong Li、Lingtong Fang、Dong Liu、Meng Gao、Aiwen Lei

  DOI：10.1021/acs.orglett.7b01548

  日期：2017.8.4

  An efficient and alternative oxidative cross-coupling strategy starting from arylboronic acids and isocyanides for the selective synthesis of amides and diaryl ketones with palladium/copper catalysis is developed. Various substituted benzamides and benzophenones could be obtained in good yields. The reaction represents an efficient and alternative strategy for the synthesis of carbonyl compounds.

  从钯/铜催化选择性合成酰胺和二芳基酮开始，开发了一种从芳基硼酸和异氰化物开始的有效且交替的氧化交叉偶联策略。可以高产率获得各种取代的苯甲酰胺和二苯甲酮。该反应代表了羰基化合物合成的有效和替代策略。
• Site-specific conjugation of linker drugs to antibodies and resulting ADCs
  申请人：SYNTHON BIOPHARMACEUTICALS B.V.

  公开号：US10407743B2

  公开（公告）日：2019-09-10

  The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumors and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.

  本发明涉及抗体-药物共轭物（ADCs），其中连接体药物通过工程半胱氨酸与抗体特异性连接，并涉及其作为药物的用途，特别是用于治疗人类实体瘤和血液恶性肿瘤，尤其是乳腺癌、胃癌、结直肠癌、尿道癌、卵巢癌、子宫癌、肺癌、间皮瘤、肝癌、胰腺癌、前列腺癌和白血病。
• Selective reduction of cysteine-engineered antibodies
  申请人：Byondis B.V.

  公开号：US10814009B2

  公开（公告）日：2020-10-27

  The present invention relates to a process for the selective reduction of cysteine-engineered antibodies comprising reacting an antibody comprising one or more engineered cysteines at positions selected from HC40, HC41,HC42, HC89, HC152, HC153, HC155, HC171, LC40, LC41, LC165, and LC168 with a compound according to formula (I), (II), (III), (IV), (V), (VI) or (VII): (I) (II) (III) (IV) (V) (VI) (VII), and to a process for the preparation of antibody conjugates, including antibody-drug conjugates (ADCs).

  本发明涉及一种选择性还原半胱氨酸工程化抗体的工艺，包括将在选自 HC40、HC41、HC42、HC89、HC152、HC153、HC155、HC171、LC40、LC41、LC165 和 LC168 的位置上包含一个或多个工程化半胱氨酸的抗体与根据式(I)、(II)、(III)、(IV)、(V)、(VI)或(VII)的化合物反应：(I)(II)(III)(IV)(V)(VI)(VII)的化合物，以及制备抗体共轭物，包括抗体-药物共轭物（ADC）的工艺。
• Duocarmycin ADCs showing improved in vivo antitumor activity
  申请人：Byondis B.V.

  公开号：US11382982B2

  公开（公告）日：2022-07-12

  The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

  本发明涉及含杜卡霉素的抗体药物偶联物(ADCs)，用于治疗表达HER2的实体瘤和血液系统恶性肿瘤，尤其是乳腺癌、胃癌、膀胱癌、卵巢癌、肺癌、前列腺癌、胰腺癌、结直肠癌、头颈部鳞状细胞癌或骨肉瘤，以及急性淋巴细胞白血病。特别地，本发明涉及用于治疗HER2免疫组化(IHC)2+或1+且HER2荧光原位杂交(FISH)阴性肿瘤状态的人类实体瘤的含杜卡霉素的ADCs。更有利的是，本发明涉及用于治疗三阴性乳腺癌(TNBC)的含杜卡霉素的ADCs。
• DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY
  申请人：Synthon Biopharmaceuticals B.V.

  公开号：US20170014525A1

  公开（公告）日：2017-01-19

  The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).